161 related articles for article (PubMed ID: 37962611)
1. In vitro and in vivo accumulation of the anticancer Ru complexes [Ru
Riisom M; Morrow SJ; Herbert CD; Tremlett WDJ; Astin JW; Jamieson SMF; Hartinger CG
J Biol Inorg Chem; 2023 Dec; 28(8):767-775. PubMed ID: 37962611
[TBL] [Abstract][Full Text] [Related]
2. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
3. The aqueous stability and interactions of organoruthenium compounds with serum proteins, cell culture medium, and human serum.
Riisom M; Eade L; Tremlett WDJ; Hartinger CG
Metallomics; 2022 Jul; 14(7):. PubMed ID: 35751650
[TBL] [Abstract][Full Text] [Related]
4. Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.
Tripathy SK; De U; Dehury N; Pal S; Kim HS; Patra S
Dalton Trans; 2014 Oct; 43(39):14546-9. PubMed ID: 25160655
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic Ru
Tsolis T; Nikolaou N; Ypsilantis K; Kougioumtzi A; Kordias D; Magklara A; Garoufis A
J Inorg Biochem; 2021 Jun; 219():111435. PubMed ID: 33819801
[TBL] [Abstract][Full Text] [Related]
6. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
[TBL] [Abstract][Full Text] [Related]
7. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
8. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
9. Differences in Stability, Cytotoxicity, and Mechanism of Action of Ru(II) and Pt(II) Complexes of a Bidentate N,O Donor Ligand.
Maji M; Acharya S; Maji S; Purkait K; Gupta A; Mukherjee A
Inorg Chem; 2020 Jul; 59(14):10262-10274. PubMed ID: 32585099
[TBL] [Abstract][Full Text] [Related]
10. Hydrolytic behaviour and chloride ion binding capability of [Ru(η6-p-cym)(H2O)3]2+: a solution equilibrium study.
Bíró L; Farkas E; Buglyó P
Dalton Trans; 2012 Jan; 41(1):285-91. PubMed ID: 22051630
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
12. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
Rafols L; Josa D; Aguilà D; Barrios LA; Roubeau O; Cirera J; Soto-Cerrato V; Pérez-Tomás R; Martínez M; Grabulosa A; Gamez P
Inorg Chem; 2021 Jun; 60(11):7974-7990. PubMed ID: 33979132
[TBL] [Abstract][Full Text] [Related]
13. Comparative solution equilibrium studies of antitumor ruthenium(η
Dömötör O; Pape VFS; May NV; Szakács G; Enyedy ÉA
Dalton Trans; 2017 Mar; 46(13):4382-4396. PubMed ID: 28287667
[TBL] [Abstract][Full Text] [Related]
14. Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes.
Purkait K; Chatterjee S; Karmakar S; Mukherjee A
Dalton Trans; 2016 May; 45(20):8541-55. PubMed ID: 27120485
[TBL] [Abstract][Full Text] [Related]
15. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
16. Studies on anticancer properties with varying co-ligands in a Ru(II) arene benzimidazole system.
Pragti ; Nayek S; Singh S; Sonawane A; Grabchev I; Ganguly R; Mukhopadhyay S
Dalton Trans; 2023 May; 52(21):7104-7118. PubMed ID: 37158792
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response.
Kaluđerović GN; Krajnović T; Momcilovic M; Stosic-Grujicic S; Mijatović S; Maksimović-Ivanić D; Hey-Hawkins E
J Inorg Biochem; 2015 Dec; 153():315-321. PubMed ID: 26428537
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biomolecular interactions and cytotoxic activity of organometallic binuclear Ru(II) complexes of ferrocenyl thiosemicarbazones.
Khanvilkar P; Dash SR; Vohra A; Devkar R; Chakraborty D
J Biomol Struct Dyn; 2021 Oct; 39(16):6044-6055. PubMed ID: 32729376
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterisation and biological activities of [(p-cym)RuX(pz4lut)]n+ and [{(p-cym)RuX}2(μ-pz4lut)]n+ (X = Cl, H2O and pz4lut = α,α,α',α'-tetra(pyrazol-1-yl)-2,6-lutidine).
Tripathy SK; Surada RK; Manne RK; Mobin SM; Santra MK; Patra S
Dalton Trans; 2013 Oct; 42(39):14081-91. PubMed ID: 23938874
[TBL] [Abstract][Full Text] [Related]
20. One-pot synthesis of symmetric and asymmetric p-quinone ligands and unprecedented substituent induced reactivity in their dinuclear ruthenium complexes.
Schweinfurth D; Das HS; Weisser F; Bubrin D; Sarkar B
Inorg Chem; 2011 Feb; 50(3):1150-9. PubMed ID: 21214266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
